Cornely M E
Hautarzt. 2010 Oct;61(10):873-9. doi: 10.1007/s00105-010-1987-7.
Lipohyperplasia dolorosa and lymphedema are completely different disease entities, which are both, however, classified under lymphology. While in lipohyperplasia dolorosa a congenital lipid distribution disorder leads to a high volume insufficiency and the corresponding clinical symptoms, lymphedema is characterized by a congenital transport incompetence of the vessels or acquired disorders of transport capacity. Both lymphedemas of different genesis are familial volume alterations of the affected regions and the increase in volume is irreversible if not exclusively still in stage I or II. According to current knowledge the solid increase in volume by lymphedema is due to a malfunctioning biomechanism by which the release of additional proteoglycans in the homeostasis system of the fluid in the interstital space plays an important role. Removal of this tissue and the sponge-like substance of proteoglycans is the aim of therapeutic approaches. Manual lymph drainage and compression can evacuate the sponge but not remove it. Lymphological liposculpture is a successful dermatosurgical measure even for secondary lymphedema. Reduction of the necessity of complex hemostasis therapy to 20% of the initial value and an adjustment of the affected extremity on the healthy side, represent a clear improvement in quality of life of patients. The same dermatosurgical method, lymphological liposculpture, has been known for many years to fulfil the successfully proven purpose for the treatment of lipohyperplasia dolorosa by the removal of subcutaneous fatty tissue, present as hyperplasia and not hypertrophy. Tenderness and the necessity for complex hemostasis therapy are no longer present or no longer necessary after lymphological liposculpture for lipohyperplasia dolorosa. This condition is permanent because the congenital fatty masses do not reoccur following surgical removal. Lipohyperplasia dolorosa is therefore curable by lymphological liposculpture. For secondary lymphedema a drastic improvement in quality of life of the patient can be achieved by this method which is demonstrated by the adjustment of symmetry of the extremities and reduction or even avoidance of complex hemostasis therapy.
痛性脂肪增生和淋巴水肿是完全不同的疾病实体,但二者均归类于淋巴学范畴。在痛性脂肪增生中,先天性脂质分布紊乱导致大量容量不足及相应临床症状,而淋巴水肿的特征是先天性血管运输功能不全或后天获得性运输能力障碍。不同成因的淋巴水肿均为受累区域的家族性容量改变,若并非仅处于I期或II期,容量增加则不可逆。根据目前的认知,淋巴水肿导致的实质性容量增加是由于生物力学机制故障,其中间质空间液体稳态系统中额外蛋白聚糖的释放起重要作用。清除该组织及蛋白聚糖样海绵状物质是治疗方法的目标。手法淋巴引流和加压可排出海绵状物质但无法清除。淋巴学脂肪雕塑术即使对于继发性淋巴水肿也是一种成功的皮肤外科手术措施。将复杂止血治疗的必要性降低至初始值的20%,并使患侧肢体与健侧相匹配,这明显改善了患者的生活质量。同样的皮肤外科方法,即淋巴学脂肪雕塑术,多年来一直被认为可通过切除增生而非肥大的皮下脂肪组织,成功实现治疗痛性脂肪增生的既定目的。痛性脂肪增生经淋巴学脂肪雕塑术后,压痛及复杂止血治疗的必要性不再存在或不再必要。这种情况是永久性的,因为先天性脂肪团在手术切除后不会复发。因此,痛性脂肪增生可通过淋巴学脂肪雕塑术治愈。对于继发性淋巴水肿,该方法可显著改善患者生活质量,表现为肢体对称性改善以及减少甚至避免复杂止血治疗。